BioSpace News Archive

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 27th, at 4:30 p.m. ET to discuss first quarter 2022 financial results and provide a general business update.

The American Foundation for the Blind announced the publication of the Journey Forward research report, examining the impact of the COVID-19 pandemic on U.S. adults who are blind, low vision, or deafblind.

Kleiner Device Labs today announced that its new KG2™ Surge™ flow-thru interbody system was recognized with the Bronze award in the 2022 Medical Design Excellence Awards (MDEA) in the Implant and Tissue-Replacement Products category.

Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today highlighted data being presented in collaboration with Stimunity during the American Association for Cancer Research (AACR) 2022 Annual Meeting.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced the presentation of preclinical data and a trial in progress overview for its immunotherapy candidate NL-201, an IL-2 and IL-15 agonist, at the American Association for Cancer Research (AACR) Annual Meeting.

OncoNano Medicine, Inc. today announced positive results from a preclinical study of ONM-501, a novel dual-activating polyvalent STING (STimulator of INterferon Genes) agonist for immuno-oncology applications.

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the presentation of preclinical data on the company’s anti-CD27 agonist lead antibodies at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Awakn Clinics Bristol was Awakn’s and the UK’s first medical psychedelic-assisted therapy clinic.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), today announced positive preclinical data demonstrating potent T cell responses, potential novel combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), today announced preclinical data supporting the clinical development and mechanistic understanding of BAF inhibition through the BRG1 (SMARCA4) and BRM (SMARCA2) dual inhibitor, FHD-286, for the treatment of cancer, at the 2022 American Association for Cancer Research (AACR) Annual Meeting.